Annovis Announces Open-Label Study for Parkinson’s Patients
Annovis plans a 500-patient, U.S.-based open-label extension in Parkinson’s disease starting January 2026, dosing once-daily 30 mg buntanetap for...
Altimmune’s Pemvidutide Shows Success in Phase 2b MASH Trial
Pemvidutide delivered statistically significant 48-week improvements on multiple non-invasive fibrosis markers in the Phase 2b IMPACT trial. Mean ELF...
VTV & M42 Submit Phase 2 Diabetes Study Protocol in UAE
vTv Therapeutics has submitted a Phase 2 protocol to the Department of Health, Abu Dhabi, for cadisegliatin in insulin-treated...
Pioneering Glioma Therapy Shows Successful Clinical Results
In a first-in-human study of 11 patients with recurrent malignant glioma, NXL-004 reported no drug-related serious adverse events or...
Actuate to Present Phase 2 Pancreatic Cancer Data at ASCO GI
Actuate Therapeutics’ randomized Phase 2 trial of elraglusib added to gemcitabine/nab-paclitaxel in previously untreated metastatic pancreatic ductal adenocarcinoma has...
New Hope for T1D: First Patient Dosed in Safeguard Trial
SAB Biotherapeutics has dosed the first patient in SAFEGUARD, a Phase 2b registrational study evaluating SAB-142, a fully human...
Pivotal Alzheimer’s Trial Begins Final Patient Treatment
Actinogen has fully randomized 247 patients to its Phase 2b/3 XanaMIA study in mild to moderate Alzheimer’s disease, and...
Ovid Reports Phase 1 Data for Unique KCC2 Activator OV350
In a randomized, placebo-controlled Phase 1 study of 16 healthy volunteers, intravenous OV350 met its primary safety, tolerability, and...
Pioneering Pancreatic Cancer Trial Randomizes First Patient
Revolution Medicines has randomized the first patient in RASolute 304, a global, open-label Phase 3 study testing daraxonrasib as...
Orelabrutinib Phase 2b Lupus Study Meets Primary Endpoint
In a 187-patient Phase 2b study in systemic lupus erythematosus, orelabrutinib 75 mg once daily achieved a 57.1% SRI-4...